SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
AMGN Analysis & Videos »
AMGN: Bull or Bear?
Three Health Care Stocks to Sell: Amgen, Baxter, Becton Dickinson
AMGN
-80.77%
in
1063 days
Filed under: Baxter Intl (BAX), Amgen Inc (AMGN), Stocks to Sell  Health care stocks are seen as low-risk investments by many stock market investors. After all - folks will always get sick, right? While that may be the case, it's an oversimplification to say that all health care stocks then have a built in customer base. The fact of the matter is that the health care industry has seen a big shakeup in the wake of Obama's health care reform bill and not all stocks in this sector are adapting well.
To keep your portfolio in perfect health, here are three big-name health care blue chips to sell n...
|
Trading FDA, Clinical Trial Binary Events: $AMGN $CPIX $RHHBY $VVUS
AMGN
|
|
|
+80.81%
in
1066 days
Below are some Regulatory Catalyst Index updates for companies with recent FDA and clinical trial related news... <font> Amgen (NASDAQ:AMGN) announced today that the FDA issued a priority (six-month) review for its Biologics License Application (BLA) for Denosumab (a subcutaneous RANK Ligand inhibitor) (bone protecting drug) seeking approval for reduction of skeletal related events (SREs) in patients with advanced cancer. </font> <> <font> Roche (OTC:RHHBY) has a scheduled Oncologic Drugs FDA Advisory Committee meeting scheduled for tomorrow to review the previously issued accelerat...
|
YM BioSciences: Trading Below Cash with Multiple Catalysts
AMGN
|
|
|
-11.89%
in
345 days
(closed on 07/19/10)
YM BioSciences (AMEX:YMI) (TSE:YM) (US$0.58) currently trades at a negative enterprise value of about $10 million (M), which includes $43M in cash, zero debt, and a trailing 12-month cash burn rate of about $18M. YMI has about 58.5M shares outstanding and 65M shares of common stock on a fully diluted basis, which equates to a market cap of about US$34M and US$38M, respectively. <o:p> </o:p> http://biomedreports.com/articles/most-popular/5071-ym-biosci... <o:p> </o:p> <> Nimotuzumab (nimo) (an IgG1, humanized epidermal growth factor or EGFR targeting mo...
|
FDA Calendar Updates: Acorda, Amgen, DOR BioPharma
AMGN
|
|
|
-4.77%
in
4 days
(closed on 08/08/09)
Below is a summary of updates to the BioMedReports.com FDA Calendar , which includes a database of 290 entries as of 8/4/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, ANDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage clinical trial result...
|
Amgen 2Q Earnings Beat, Raises Guidance, Denosumab Deal
AMGN
|
|
|
+4.53%
in
8 days
(closed on 08/04/09)
Amgen (NASDAQ:AMGN) reported adjusted earnings per share (EPS) of $1.29 for 2Q09, an increase of 13% compared to $1.14 for the 2Q08. Adjusted net income increased 6% to $1.3 billion during 2Q09 versus $1.2 billion during 2Q08. Total revenue declined by 1% during 2Q09 to $3.71 billion versus $3.76 billion during 2Q08. The Company provided revenue guidance for 2009 that is trending towards the upper end of its current guidance range of $14.4-14.8 billion. Amgen now expects 2009 adjusted EPS to be in the range of $4.80-4.95, an increase from the previous range of $4.55 to $4.75. The Company no...
|
FDA Calendar: 2H09 Binary Event Trades
AMGN
|
|
|
-0.25%
in
1 day
(closed on 07/27/09)
<> Below is a selection of companies included in the BioMedReports.com FDA Calendar database of 281 entries as of 7/26/09 with expected binary event catalysts through year-end. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the ...
|
FDA Calendar Updates: Amgen, Bayer, Biogen, Noveko, Peplin, Transdel
AMGN
|
|
|
+0.63%
in
18 days
(closed on 07/26/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 246 entries as of 7/8/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending...
|
FDA Calendar Updates: EURX, AMGN, FOLD, ONTY, MEDX
AMGN
|
|
|
+18.73%
in
16 days
(closed on 07/08/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st...
|
New Index of Highly Defensive Market Cap Leaders
AMGN
|
|
|
-9.19%
in
117 days
(closed on 06/22/09)
The ETF Innovators Highly Defensive Index contains 40 market cap leading companies which are based in either North America or Europe from the defensive industry groups (A-K) specified below. www.BioMedReports.com - Mike Havrilla (A) Mass Merchant Discount Retailer (1): Wal-Mart (WMT) <> <> (B) Consumer Staples (12): Coca-Cola (KO), Colgate-Palmolive (CL), Diageo (DEO), General Mills (GIS), Danone (GDNNY), Kraft Foods (KFT), Nestle (NSRGY), PepsiCo (PEP), Philip Morris International (PM), Procter & Gamble (PG), Reckitt Benckiser (RBGPF), Unilever (UN) <><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>< />...
|
Bullish on AMGN ...
AMGN
|
|
|
+0.00%
in
1 minute
(closed on 02/25/09)
New Index of Highly Defensive Market Cap Leaders The ETF Innovators Highly Defensive Index contains 40 market cap leading companies which are based in either North America or Europe from the defensive industry groups (A-K) specified below. www.BioMedReports.com - Mike Havrilla (A) Mass Merchant Discount Retailer (1): Wal-Mart (WMT) <> <> (B) Consumer Staples (12): Coca-Cola (KO), Colgate-Palmolive (CL), Diageo (DEO), General Mills (GIS), Danone (GDNNY), Kraft Foods (KFT), Nestle (NSRGY), PepsiCo (PEP), Philip Morris International (PM), Pro<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>< />...
|
Create Your Own Highly Defensive ETF
AMGN
|
|
|
+2.58%
in
35 days
(closed on 02/25/09)
Create Your Own Highly Defensive ETF The table at my website link below contains 35 companies included in the ETF Innovators [ETFI] Highly Defensive PerformIdex which are based in the U.S., Canada, and Europe with market caps over $10B that are the leaders by market cap in their defensive industry groups. The index includes 23 consumer staples and healthcare companies, with the remaining 12 companies chosen from a variety of other defensive industry groups. <> (A) Mass Merchant Dis...
|
A New Index of Health Product Innovators
AMGN
|
|
|
-7.57%
in
16 days
(closed on 01/21/09)
<> 
The accompanying table includes statistics and all 23 companies in the ETF Innovators [ETFI] Global Health Innovators Index of companies with market caps over $250M which received FDA approval in the past 12 months for an original new drug product or medical device.
The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding all new formulations of existing drugs, generic drugs, and label extensions for existing products). Also, companies whi...
|
Four Healthy Stocks Trading Above Moving Averages
AMGN
|
|
|
+2.65%
in
4 days
(closed on 01/05/09)
Amgen (AMGN), AspenBio Pharma (APPY), BioDelivery Sciences (BDSI), and Cypress Bioscience (CYPB) are four healthcare stocks that I follow which are poised to close out a rough 2008 for the overall market trading above their 50 and 200-day moving averages, in addition to having significant catalysts in 2009 which may lead to further gains. Below is a summary of the 2009 catalysts for these companies and click on the names or tickers below for a link to all of the articles on my blog for each stock: <> Amgen filed a BLA for bone drug denosumab in the following two indicatio...
|
People Bullish on AMGN
People Bearish on AMGN
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on AMGN |
Stock update and watch list 7/29/08
- Due to difficulties understanding the socialpicks system regarding changing rating from buy to hold and thus resetting the performance, I wanted to sum...
|
Portfolio results thru 8/8/08
- Portfolio at www.updown.com - started 1/11/08
9.8% return includes dividends and commission.
Started socialpicks on 6/30. some stocks here are not in...
|
More Resources
|
About Amgen Inc
- Answers.com
A lot of investors think Amgen (
Spring is finally here, which means it's time to break out the broom and dustpan for some spring cleaning.
